Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 5

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 5
---
 statements prove to be inaccurate, the inaccuracy may be material. In light of the

significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or

warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Moreover,

forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any

obligation to update them in light of new information, future developments or otherwise, except as required by law. These

forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this annual

report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or

incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all

potentially available relevant information. In light of these risks,uncertainties and assumptions, you should not place undue

reliance on any forward looking statements contained herein.

You should read this annual report and the documents that we reference in this annual report and have filed as exhibits

completely and with the understanding that our actual future results may be materially different from what we expect. We qualify

all of our forward-looking statements by these statements.

Abbreviations Principal abbreviations used in the Annual Report on Form 20-F

| ADR     | American Depositary Receipt                                                                                           |
| ADS     | American Depositary Share                                                                                             |
| AFEP    | Association française des entreprises privées (FrenchAssociation of Large Companies)                                  |
| AMF     | Autorité des marchés financiers (the French marketregulator)                                                          |
| ANDA    | Abbreviated New Drug Application                                                                                      |
| BLA     | Biologic License Application                                                                                          |
| BMS     | Bristol-Myers Squibb                                                                                                  |
| CEO     | Chief Executive Officer                                                                                               |
| CER     | Constant exchange rates                                                                                               |
| CGU     | Cash generating unit                                                                                                  |
| CHC     | Consumer Healthcare, Opella                                                                                           |
| CHMP    | Committee for Medicinal Products for Human Use                                                                        |
| COVALIS | Sanofi committee for internal occupational exposurelimits (Comité des Valeurs Limites Internes Sanofi)                |
| CSR     | Corporate Social Responsibility                                                                                       |
| CVR     | Contingent value right                                                                                                |
| EFPIA